GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Research & Development

Argenica Therapeutics (ASX:AGN) Research & Development : A$6.12 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Argenica Therapeutics's Research & Development for the six months ended in Dec. 2024 was A$2.92 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was A$6.12 Mil.


Argenica Therapeutics Research & Development Historical Data

The historical data trend for Argenica Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argenica Therapeutics Research & Development Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Research & Development
0.42 2.50 4.31 6.02

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only 1.93 2.38 2.82 3.20 2.92

Argenica Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$6.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Argenica Therapeutics  (ASX:AGN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Argenica Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of Argenica Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Argenica Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics Headlines

No Headlines